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 IMMUNITY 
In biology, immunity is the balanced state of having adequate biological 
defenses to fight infection, disease, or other unwanted biological invasion, while 
having adequate tolerance to avoid allergy, and autoimmune diseases.
Introduction
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Fig. 2 
Innate immunity, also called natural or native immunity. This immunity is by 
virtue of genetic constitutional make-up. It is there in the body without any external 
stimulation or a previous infection. It is divided into two types:- (a) Non-Specific 
innate immunity: A degree of natural resistance to all infections in general. (b) 
Specific innate immunity: This is a natural resistance to a particular kind of germ 
only. Some races or specific individual do not suffer from certain infectious diseases. 
Adaptive immunity is often sub-divided into two major types depending on 
how the immunity was introduced. 'Naturally acquired immunity' occurs through 
contact with a disease causing agent, when the contact was not deliberate, whereas 
'artificially acquired immunity' develops only through deliberate actions such as 
vaccination. Both naturally and artificially acquired immunity can be further 
subdivided depending on whether immunity is induced in the host or passively 
transferred from an immune host. 'Passive immunity' is acquired through transfer of 
antibodies or activated T-cells from an immune host, and is short lived—usually 
lasting only a few months—whereas 'active immunity' is induced in the host itself by 
antigen and lasts much longer, sometimes lifelong. 
A further subdivision of adaptive immunity is characterized by the cells 
involved; humoral immunity is the aspect of immunity that is mediated by secreted 
antibodies, whereas the protection provided by cell mediated immunity involves T-
lymphocytes alone. Humoral immunity is active when the organism generates its own 
antibodies, and passive when antibodies are transferred between individuals. 
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Similarly, cell mediated immunity is active when the organisms’ own T-cells are 
stimulated and passive when T cells come from another organism. 
 
Fig. 3 
Passive immunity is the transfer of active immunity, in the form of readymade 
antibodies, from one individual to another. Passive immunity can occur naturally, 
when maternal antibodies are transferred to the foetus through the placenta, and can 
also be induced artificially, when high levels of human (or horse) antibodies specific 
for a pathogen or toxin are transferred to non-immune individuals. Passive 
immunization is used when there is a high risk of infection and insufficient time for 
the body to develop its own immune response, or to reduce the symptoms of ongoing 
or immunosuppressive diseases1.Passive immunity provides immediate protection, but 
the body does not develop memory, therefore the patient is at risk of being infected by 
the same pathogen later2. 
Maternal passive immunity is a type of naturally acquired passive immunity, 
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and refers to antibody-mediated immunity conveyed to a fetus by its mother during 
pregnancy. Maternal antibodies (MatAb) are passed through the placenta to the fetus 
by an FcRn receptor on placental cells. This occurs around the third month of 
gestation. IgG is the only antibody isotype that can pass through the placenta. Passive 
immunity is also provided through the transfer of IgA antibodies found in breast milk 
that are transferred to the gut of the infant, protecting against bacterial infections, until 
the newborn can synthesize its own antibodies.  
 
Fig. 4 One of the first bottles of diphtheria antitoxin produced (Dated 1895) 
Artificially acquired passive immunity is a short-term immunization induced 
by the transfer of antibodies, which can be administered in several forms; as human or 
animal blood plasma, as pooled human immunoglobulin for intravenous (IVIG) or 
intramuscular (IG) use, and in the form of monoclonal antibodies (MAb). Passive 
transfer is used prophylactically in the case of immuno deficiency diseases, such as 
hypogammaglobulinemia3. It is also used in the treatment of several types of acute 
infection, and to treat poisoning. Immunity derived from passive immunization lasts 
for only a short period of time, and there is also a potential risk for hypersensitivity 
reactions, and serum sickness, especially from gamma globulin of non-human origin.  
The artificial induction of passive immunity has been used for over a century 
to treat infectious disease, and prior to the advent of antibiotics, was often the only 
specific treatment for certain infections. Immunoglobulin therapy continued to be a 
first line therapy in the treatment of severe respiratory diseases until the 1930s, even 
after sulfonamide lot antibiotics were introduced.  
Passive or "adoptive transfer" of cell-mediated immunity, is conferred by the 
transfer of "sensitized" or activated T-cells from one individual into another. It is 
rarely used in humans because it requires histocompatible (matched) donors, which 
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are often difficult to find. In unmatched donors this type of transfer carries severe 
risks of graft versus host disease. It has, however, been used to treat certain diseases 
including some types of cancer and immunodeficiency. This type of transfer differs 
from a bone marrow transplant, in which (undifferentiated) hematopoietic stem cells 
are transferred. 
Active immunity 
 
The time course of an immune response 
Due to the formation of immunological memory, reinfection at later time 
points leads to a rapid increase in antibody production and effector T cell activity. 
These later infections can be mild or even unapparent. 
When B cells and T cells are activated by a pathogen, memory B-cells and T- 
cells develop, and the primary immune response results. Throughout the lifetime of an 
animal these memory cells will "remember" each specific pathogen encountered, and 
are able to mount a strong secondary response, if the pathogen is detected again. The 
primary and secondary responses were first described in 1921 by English 
immunologist Alexander Glenny4 although the mechanism involved was not 
discovered until later.This type of immunity is both active and adaptive because the 
body's immune system prepares itself for future challenges. Active immunity often 
involves both the cell-mediated and humoral aspects of immunity as well as input 
from the innate immune system. 
Naturally acquired active immunity occurs when a person is exposed to a live 
pathogen, and develops a primary immune response, which leads to immunological 
memory. This type of immunity is "natural" because it is not induced by deliberate 
exposure. Many disorders of immune system function can affect the formation of 
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active immunity such as immuno deficiency (both acquired and congenital forms) and 
immunosuppression. 
Artificially acquired active immunity can be induced by a vaccine, a substance 
that contains antigen. A vaccine stimulates a primary response against the antigen 
without causing symptoms of the disease. The term vaccination was coined by 
Richard Dunning, a colleague of Edward Jenner, and adapted by Louis Pasteur for his 
pioneering work in vaccination. The method Pasteur used entailed treating the 
infectious agents for those diseases so they lost the ability to cause serious disease. 
Pasteur adopted the name vaccine as a generic term in honor of Jenner's discovery, 
which Pasteur's work built upon. 
 
Fig. 5 Poster from before the 1979 eradication of smallpox, promoting vaccination 
In 1807, Bavaria became the first group to require that their military recruits 
be vaccinated against smallpox, as the spread of smallpox was linked to 
combat5. Subsequently the practice of vaccination would increase with the spread of 
war. 
There are four types of traditional vaccines:6 
 Inactivated vaccines are composed of micro-organisms that have been killed 
with chemicals and/or heat and are no longer infectious. Examples are 
vaccines against flu, cholera, plague, and hepatitis A. Most vaccines of this 
type are likely to require booster shots. 
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 Live, attenuated vaccines are composed of micro-organisms that have been 
cultivated under conditions which disable their ability to induce disease. These 
responses are more durable and do not generally require booster shots. 
Examples include yellow fever, measles, rubella, and mumps. 
 Toxoids are inactivated toxic compounds from micro-organisms in cases 
where these (rather than the micro-organism itself) cause illness, used prior to 
an encounter with the toxin of the micro-organism. Examples of toxoid-based 
vaccines include tetanus and diphtheria. 
 Subunit vaccines are composed of small fragments of disease causing 
organisms. A characteristic example is the subunit vaccine against Hepatitis B 
virus. 
Most vaccines are given by hypodermic or intramuscular injection as they are 
not absorbed reliably through the gut. Live attenuated polio and 
some typhoid and cholera vaccines are given orally in order to produce immunity 
based in the bowel. 
Immuno suppression is a reduction of the activation or efficacy of the immune 
system. Some portions of the immune system itself have immunosuppressive effects 
on other parts of the immune system, and immune suppression may occur as an 
adverse reaction to treatment of other conditions. 
In general, deliberately induced immune suppression is performed to prevent 
the body from rejecting an organ transplant, treating graft-versus-host disease after a 
bone marrow transplant, or for the treatment of auto-immune diseases such as 
systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, or Crohn's 
disease. This is typically done using medications, but may involve surgery (spleen 
removal), plasmapharesis, or radiation. 
A person who is undergoing immune suppression, or whose immune system is 
weak for other reasons (for example, chemotherapy or HIV), is said to be immuno 
compromised. An immune suppressant is any agent that weakens the immune system, 
including immunosuppressive drugs and some environmental toxins. 
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Fig. 6 Micrograph showing an opportunistic infection due to immunosuppression - 
large (blue) cell below-center-left infected with a polyomavirus. Urine cytology 
specimen. 
Immunosuppressive drug 
Administration of immunosuppressive medications or immunosuppressants is 
the main method of deliberately induced immunosuppression. In optimal 
circumstances, immunosuppressive drugs are targeted only at any hyperactive 
component of the immune system, and in ideal circumstances would not cause any 
significant immunodeficiency. However, in essence, all immunosuppressive drugs 
have the potential to cause immunodeficiency. Immunodeficiency can cause increased 
susceptibility to opportunistic infections and decreased cancer immunosurveillance. 
The term immunotoxin is also sometimes used (incorrectly) to label undesirable 
immunosuppressants, such as various pollutants. Immunosuppressants may be 
prescribed when a normal immune response is undesirable, such as in autoimmune 
diseases. 
Cortisone was the first immunosuppressant identified, but its wide-ranging 
side-effects limited its use. The more specific azathioprine was identified in 1959, but 
it was the discovery of ciclosporin in 1970 that allowed significant expansion of 
kidney transplantation to less well-matched donor-recipient pairs as well as broad 
application to liver transplantation, lung transplantation, pancreas transplantation, and 
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heart transplantation. After organ transplantation, the body will nearly always reject 
the new organ(s) due to differences in human leukocyte antigen haplotypes between 
the donor and recipient. As a result, the immune system detects the new tissue as 
"foreign", and attempts to remove it by attacking it with recipient white blood cells, 
resulting in the death of the donated tissue. Immunosuppressants are given as an 
attempt to prevent this rejection; the side-effect is that the body becomes more 
vulnerable to infections and malignancy, as in advanced HIV infection.] At the same 
time, people with previous cancer who require immune suppression are not more 
likely to have a recurrence7. 
Immunodeficiency 
Non-deliberate immune suppression can occur in, for example, malnutrition, 
aging, many types of cancer (such as leukemia, lymphoma, multiple myeloma), and 
certain chronic infections such as Human Immunodeficiency virus (HIV)8. The 
unwanted effect in non-deliberate immune suppression is immunodeficiency that 
results in increased susceptibility to pathogens such as bacteria, viruses, or fungi. 
Immunodeficiency is also a potential adverse effect of many 
immunosuppressant drugs. In this sense, the scope of the term immune suppression in 
general includes both beneficial and potential adverse effects of decreasing the 
function of the immune system, whereas the term immunodeficiency in general refers 
solely to the adverse effect of increased risk for infection. 
Immunosuppressants in Organ Transplantation 
What are immunosuppressants? 
Immunosuppressants are a class of drugs that suppress the immune response 
through various mechanisms. In organ transplantation, immune suppressants are used 
to prevent the body from either recognition or attacking the foreign organ via various 
immune responses. They should only be used under the supervision of appropriately 
trained and experienced staff. The types of drugs that use for immune suppression in 
organ transplant are: 
 Calcineurin inhibitors (cyclosporin, tacrolimus) 
 Corticosteroids (eg: methylprednisolone, dexamethasone, prednisolone) 
 Cytotoxic immunosuppressants (azathioprine, chlorambucil, cyclo-
phosphamide, mercaptopurine, methotrexate) 
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 Immunosuppressant antibodies (eg: antithymocyte globulins, basiliximab, 
infliximab) 
 Sirolimus derivatives (everolimus, sirolimus) 
 Other immunosuppressants (mycophenolate) 
Immune suppressants used for: 
 Preventing organ rejection and reverse acute rejection in organ transplantation. 
 Prevent and treat graft-versus-host disease. 
 Minimise destruction of affected tissues in autoimmune and inflammatory 
diseases. 
Drug treatment 
Transplant rejection involves the body producing T and B cell and immune 
responses that recognise markers on foreign tissue called antigens. Treatment 
regimens used to prevent rejection employ drugs from different classes taking 
advantage of their complementary actions and minimising toxicity. Drug choice 
depends on the organ being transplanted and is tailored for each individual to 
minimise transplant-related morbidity. 
Double drug treatment – usually a calcineurin inhibitor such as (Tacrolimus) 
or (cyclosporine) with either Imuran (azathioprine) or CellCept (mycophenolate). 
Triple drug treatment – usually a calcineurin inhibitor such as (Tacrolimus) or 
(cyclosporine), a corticosteroid and either  (azathioprine) or  (mycophenolate). 
Quadruple drug treatment – as for triple drug treatment plus an induction 
course with an immunosuppressant antibody (antithymocyte globulin, basiliximab or 
daclizumab). 
Immunosuppression for organ transplants usually involves triple or quadruple 
drug treatment. The intensity of immune suppression is initially high but tends to be 
reduced to a maintenance level that is determined by individual factors and the type of 
organ transplant.  
Initial Treatment 
Initially a specialist may give a corticosteroid and either (azathioprine) or 
mycophenolate (sometimes with a calcineurin inhibitors such as (tacrolimus) or 
(cyclosporin) for initial immune suppression immediately before cadaveric donor 
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transplantation, or for several days before planned live donor transplantation. 
Mechanism of immune suppressants: 
Calcineurin inhibitors 
Calcineurin inhibitors react in the body to block the activity of calcineurin. 
This results in controlling the body’s immune response and reducing the body 
recognising and attacking the foreign organ. 
Neoral (cyclosporin) is available as a microemulsion, which has greatly 
enhanced its oral bioavailability, with much less variation in absorption within and 
between patients. 
Evidence suggests that (tacrolimus) may be slightly more efficacious than 
(cyclosporin) and they are now used in equal numbers of patients worldwide. 
Absorption is hindered by food, so usually it needs to be taken on an empty stomach. 
Sirolimus is a recently developed immunosuppressant, which is very similar to 
Prograf (tacrolimus). It has many adverse effects, but has much less renal toxicity 
than calcineurin inhibitors, and is currently mainly used in lung transplantation to 
‘rescue’ patients from chronic renal failure, by substituting it for (cyclosporin). 
Cell cycle inhibitors 
Imuran (azathioprine) is used in 60% of patients and mycophenolate mofetil in 
40%. These drugs stop the production of cells called B and T cell that cause the 
immune response. 
Corticosteroids 
Corticosteroids are thought to reduce the synthesis and secretion of a variety 
of inflammatory mediators. 
Side effects of immunosuppressants 
The side effects for each type of medication vary but the most common side 
effects that occur to less than 10% of patients are: 
 Alopecia 
 Dyspepsia 
 Increased susceptibility to infections (eg: oral, vaginal and 
intertriginous candidiasis) 
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 Masking of signs of infection 
 Increased appetite 
 Delayed wound healing 
Some of the rare serious side effects that can occur in less than 1% are: 
 Muscle weakness and wasting (particularly symptomatic on drug 
withdrawal) 
 Amenorrhoea 
 Psychosis 
 Euphoria 
 Depression 
 Hirsutism 
 Gingival hyperplasia 
Immunosuppressants and malignancy 
Immunosuppression increases the chance of getting skin cancer so take 
additional measures to protect the skin from the sun such as wearing protective 
clothing, wearing sunscreen and avoiding exposure to the sun for prolonged periods 
of time.  
Overview of immunosuppression in liver transplantation 
Due to advances in immunosuppression and improvements in surgical 
techniques, liver transplantation has become an extremely successful treatment option 
for patients with end-stage liver disease, with one-year graft survival rates exceeding 
80%9. Currently, there are eight patients worldwide who have survived more than 
three decades after liver transplantation10. 
Organ transplantation initially came to light with the first successful kidney 
transplantation in 1954 on monozygotic twins; however, immunosuppression was 
limited to total body irradiation which was largely fatal11,12. With the invention of 6-
mercaptopurine (6-MP) and azathioprine (AZA) in the 1950s along with the 
introduction of corticosteroids as combination therapy by Starzl in the 1960s, there 
was noticeable improvement in kidney allograft survival, although one-year survival 
still did not exceed 50%. Multiple interventions including splenectomy, thymectomy 
and thoracic duct drainage were employed with minimal success. 
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The first successful human liver transplant was performed by Thomas Starzl in 
Denver in 1967 on an 18-month-old child with unresectable hepatoblastoma10. The 
immunosuppressive regimen included anti-lymphocyte globulin (ALG), AZA and 
prednisolone and the child survived for more than a year. 
However, the next significant breakthrough in immunosuppression did not 
occur until the discovery of cyclosporine (CYA) in 1972 from the soil fungus Tolypo-
cladiuminflatum. Borel et al13 first described its remarkable immunosuppressive 
properties in 1976 and by the 1980s there was international affirmation of its 
effectiveness. CYA quickly became the standard of care for maintenance 
immunosuppression in solid organ transplant recipients. This paved the way for the 
current era of liver transplantation, which has since continued to evolve with the 
discovery of multiple novel immunosuppressive agents. 
IMMUNOSUPPRESSION 
Effective immunosuppression in transplantation relies on preventing the 
immune system from rejecting the allograft while preserving immunologic control of 
infection and neoplasia. Although the mechanism is not completely understood, 
transplanted livers rarely reject compared to other organs, do not require an HLA-
matched donor, and may offer a protective effect for other simultaneously 
transplanted organs14,15. Both micro- and macrochimerism models have been used to 
explain this phenomenon, as well as that of hepatic dissolution of donor specific 
antibodies. 
Ideally, the long-term objective is to achieve immune tolerance or the ability 
to alter the recipient’s immune system in order to promote long-term graft function 
without immunosuppressive therapy, while maintaining immunity to infectious 
agents16. Unfortunately, except for a small minority of patients (approximately 20%) 
who have been successfully weaned off immunosuppressive medications, most 
experience immunologic rejection with the discontinuation of these drugs and have to 
be maintained on at least low doses of these medications17-21. 
Immunosuppressive regimens include calcineurin inhibitors, anti-metabolites, 
mTOR inhibitors, steroids and antibody-based therapies. These agents target different 
sites in the T cell activation cascade, usually by inhibiting T cell activation or 
proliferation or via T cell depletion. The selection of agents is based on an 
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individual’s medical history as well as on institution experience and preference. Most 
immunosuppressive regimens combine drugs with different sites of action of T cell 
response, allowing for dosage adjustments to minimize side effects and toxicities. 
Currently, the mainstay of maintenance immunosuppressive regimens are calcineurin 
inhibitors (CNIs), used in greater than 95% of transplant centers upon discharge, 
although there is a known increased risk of renal impairment22,23, metabolic 
derangements, neurotoxicity and de novo malignancies24 with the long-term use of 
these medications. 
Calcineurin Inhibitors 
CYA and tacrolimus are the two CNIs approved for use in organ 
transplantation and are the principal immune suppressives used for maintenance 
therapy. The routine use of these medications in liver transplant recipients has 
dramatically decreased the incidence of rejection and graft loss. The primary mode of 
action is inhibition of T cell activation. CYA binds to cyclophilin which results in 
inhibition of the calcium/calmodulin-dependent phosphatase, calcineurin. The binding 
to cyclophilin interferes with calcineurin’s de-phosphorylation of nuclear factor of 
activated T cells (NFAT), preventing translocation of NFAT into the nucleus and up-
regulation of pro-inflammatory cytokines. The end result is the inhibition of IL-2 gene 
transcription and T cell activation and proliferation. Tacrolimus also inhibits 
calcineurin but binds specifically to FK506-binding protein (FKBP-12). 
The immunosuppressive effects of the CNIs are related to total drug exposure 
which can be estimated by measuring blood 12-h troughs. The potency of tacrolimus 
is estimated to be 100 times greater on a molar level when compared to CYA. 
Although several earlier studies showed tacrolimus to be superior to CYA in the 
prevention of cellular rejection25-27, another more recent multi-center trial showed no 
significant differences between the two medications with regard to acute rejection 
episodes, death or graft loss28. Both CNIs are metabolized principally by the 
cytochrome P450 system and therefore have significant interactions with multiple 
medications requiring careful monitoring of drug levels  
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Table No. 1 
COMMON SIDE EFFECTS OF IMMUNOSUPPRESSIVE AGENTS 
DRUG ADVERSE EFFECTS 
Tacrolimus Nephrotoxicity, neurotoxicity1, diabetes1, hyperkalemia, 
metabolic acidosis, hypertension, hyperlipidemia 
Cyclosporine Nephrotoxicity, neurotoxicity, diabetes, 
hyperlipidemia1, hypertension1, hyperkalemia, metabolic 
acidosis, gingival hyperplasia, hypertrichosis 
MMF Myelosuppression, gastrointestinal side effects, viral 
infections (CMV, HSV), spontaneous abortions in 
pregnant women 
Sirolimus Hyperlipidemia, myelosuppression, proteinuria, poor 
wound healing, pneumonitis, skin rash 
Corticosteroids Diabetes, hypertension, obesity, osteoporosis, avascular 
necrosis, growth retardation, Cushingoid features, 
psychosis, poor wound healing, adrenal suppression, 
cataracts 
Antimetabolites 
Both mycophenolatemofetil (MMF) and mycophenolate sodium (MPS) 
undergo immediate first-pass metabolism in the liver into the active compound 
mycophenolic acid (MPA), which was first discovered in 189329. However, the 
immunosuppressive properties of MPA were not recognized until the 1990s. MPA 
inhibits inosine-5’-monophosphate dehydrogenase (IMPDH)30, the rate-limiting 
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enzyme in the de novo synthesis of guanosine nucleotides. Inhibition of the IMPDH 
pathway results in selective blockade of lymphocyte proliferation31. 
The major advantage in using the MPAs is their lack of renal toxicity. In 
patients with pre-existing renal disease, they have been used in conjunction with low-
dose CNIs as part of a renal-sparing protocol with promising results32,33. Ideally, these 
medications should be initiated when renal dysfunction is first noted, although 
emerging data suggests the benefits of MPAs in reversing long-standing renal disease 
due to its association with decreased TGF-β levels34-36. MPAs are rarely used as 
monotherapy in transplant recipients given their higher rates of rejection compared to 
the CNIs37,38, although more recent data demonstrate the safety of this approach when 
carried out carefully39,40. However, in patients previously on CNIs or mTOR 
inhibitors with evidence of acute rejection, MPAs are often added as supplemental 
immunosuppressive therapy. 
Azathioprine is another antimetabolite which was predominantly used for the 
prevention of rejection in the 1960s but has since been largely replaced by the MPAs. 
It is selectively used in a few centers in combination with other immunosuppressive 
medications, primarily CNIs and steroids. 
mTOR Inhibitors 
The two mTOR inhibitors approved for organ transplantation are sirolimus 
(SRL) and everolimus (EVL), although neither has been approved for use in liver 
transplantation to date. They bind intracellularly to FK506 binding protein (FKBP12) 
but unlike tacrolimus, they do not inhibit calcineurin activity. Rather, the complex is a 
highly specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1)41 
which has a direct effect on the cell signaling pathway required for cell cycle 
progression. This subsequently inhibits IL-2 signaling to T cells, thus preventing T 
cell proliferation. Similar to the CNIs, sirolimus is metabolized by the cytochrome 
P450 system and requires therapeutic drug monitoring (Table11). 
The first reported study illustrating the effectiveness of sirolimusmonotherapy 
for maintenance of immunosuppression in liver transplantation was in 1999 by 
Watson et al42. However, two subsequent large studies examining sirolimus de novo 
therapy with tacrolimus and corticosteroids were terminated early due to excess 
hepatic artery thrombosis (HAT). As a result, sirolimus carries a black box label 
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warning which cautions against the possible development of early post-transplant 
HAT. Subsequent studies have since disputed this finding43-45 however, mTOR 
inhibitors are rarely used as de novo therapy. 
Importantly, in patients with CNI-induced nephrotoxicity, conversion to 
sirolimus therapy has proved to be effective with ensuing improvements in renal 
function46-48. Again, sirolimus conversion should be initiated early since late 
conversion rarely improves chronic renal dysfunction49. In fact, several studies have 
shown that in patients with pre-existing renal disease, sirolimus can worsen 
nephrotoxicity and promote proteinuria50-52. 
Recent studies have also shown potential anti-tumor properties of sirolimus53-
56
 which might be of importance in patients undergoing liver transplantation for HCC. 
Zimmerman et al57 examined the role of sirolimus-based maintenance therapy in post-
transplant recipients with a history of HCC and found that overall survival was 
increased in the sirolimus arm compared to the CNI arm. Clinical trials examining the 
anti-cancer effects of mTOR inhibitors in liver transplant recipients with HCC have 
been encouraging58 and new trials are ongoing. 
Antibody-Based Therapies 
Polyclonal antibodies 
Polyclonal antibodies, including anti-thymocyte (ATG) and anti-lymphocyte 
globulins (ALG), have been used since the early days of liver transplantation and are 
prepared by inoculating rabbits or horses with human lymphocytes or thymocytes. 
Their mechanism of action is rapid lymphocyte depletion due to complement-
mediated cell lysis and uptake by the reticuloendothelial system (RES) of opsonized T 
cells59. In addition, they may also cause partial T cell activation and blockade of T 
cell proliferation60. Polyclonal antibodies were routinely used as induction therapy in 
liver transplantation along with corticosteroids and AZA before discovery ofCYA. 
Lymphocyte depletion is believed to play a role in preparing the recipient’s 
immune system to adapt and recognize the transplanted organ as self and prevent 
destruction of the allograft. Accordingly, studies have shown that ATG administration 
results in regulatory T cell (Treg) expansion in vitro and in vivo61-63. Tregs or 
suppressor T cells are responsible for preventing activation of the immune system and 
maintaining tolerance to self-antigens. 
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Currently, approximately 20% of transplant centers use these agents for 
induction purposes64 and recent data support the administration of thymoglobulin 
induction to delay CNI use and avoid renal toxicity without increasing the risk of 
rejection or HCV recurrence65-67. A few studies have also successfully shown the 
benefit of using these medications as induction therapy to avoid post-transplant 
corticosteroid use68,69 without an increased incidence of acute rejection. This is 
especially important in HCV recipients where high-dose pulsed corticosteroid therapy 
can significantly accelerate liver fibrosis. At present, anti-lymphocyte antibodies are 
used extensively to treat steroid-resistant acute rejection and are successful in 70%-
96% of patients70-72. 
Monoclonal antibodies 
Monoclonal antibodies include the anti-IL-2 receptor (CD25) antibodies, anti-
CD52 antibody and muromonab-CD3 (OKT3). The two anti-IL-2 receptor antibodies 
approved for clinical use are basiliximab (Simulect), a chimeric protein, and 
daclizumab (Zenapax), a humanized protein. Both antibodies are specific for the α 
chain of the IL-2 receptor, CD25, which is only expressed on activated T cells. These 
antibodies remain in the circulatory system for weeks after initiation of therapy and 
have been used successfully with low-dose CNIs in preventing acute rejection in the 
early post-transplant period73-75. They also have fewer side effects compared to the 
anti-lymphocyte globulins, rarely cause the typical first-dose infusion reactions and 
are associated with less risk of opportunistic infections and PTLD. 
Muromonab-CD3 (OKT3) targets the CD3 molecule on T cells and causes 
depletion of lymphocytes by massive T cell lysis76 and cytokine release77. This 
profound cytokine release can lead to pulmonary edema and acute respiratory distress 
and rarely, intra-graft thrombosis and aseptic meningitis78,79. As a result, 
antihistamines and intravenous steroids are routinely used as pre-medication to reduce 
this “cytokine release syndrome”. Several days after OKT3 administration, T 
lymphocytes no longer express CD3 and are considered to be immunologically 
incompetent80. OKT3 is primarily used in liver transplantation for steroid-resistant 
acute rejection81,82 and has a success rate of complete recovery in 50% of patients. 
OKT3 use should be limited in the HCV population as several studies have confirmed 
exacerbation of disease recurrence with this agent83,84. 
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PROPOLIS 
Propolis or bee glue is a resinous mixture that honey bees produce by mixing 
saliva and beeswax with exudate gathered from tree buds, sap flows, or other 
botanical sources. It is used as a sealant for unwanted open spaces in the hive. 
Propolis is used for small gaps (approximately 6 millimeters (0.24 in) or less), while 
larger spaces are usually filled with beeswax. Its color varies depending on its 
botanical source, the most common being dark brown. Propolis is sticky at and above 
room temperature, 20°C (68°F). At lower temperatures, it becomes hard and very 
brittle. 
 
Fig. 7 Resins in hive 
The composition of propolis varies from hive to hive, from district to district, 
and from season to season85. Normally, it is dark brown in color, but it can be found 
in green, red, black, and white hues, depending on the sources of resin found in the 
particular hive area. Honey bees are opportunists, gathering what they need from 
available sources, and detailed analyses show that the chemical composition of 
propolis varies considerably from region to region, along with the vegetation. In 
northern temperate climates, for example, bees collect resins from trees, such as 
poplars and conifers (the biological role of resin in trees is to seal wounds and defend 
against bacteria, fungi and insects). "Typical" northern temperate propolis has 
approximately 50 constituents, primarily resins and vegetable balsams (50%), waxes 
(30%), essential oils (10%), and pollen (5%). Propolis also contains persistent 
lipophilic acaricides, a natural pesticide that deters mite infestations86. 
In neotropical regions, in addition to a large variety of trees, bees may also 
gather resin from flowers in the genera Clusia and Dalechampia, which are the only 
known plant genera that produce floral resins to attract pollinators87. Clusia resin 
contains polyprenylated benzophenones88-90. In some areas of Chile, propolis contains 
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viscidone, a terpene from Baccharis shrubs91, and in Brazil, naphthoquinone epoxide 
has recently been isolated from red propolis92, and prenylated acids such as 4-
hydroxy-3,5-diprenyl cinnamic acid have been documented93. An analysis of propolis 
from Henan, China found sinapinic acid, isoferulic acid, caffeic acid, and chrysin, 
with the first three compounds demonstrating antibacterial properties94. Also, 
Brazilian red propolis, largely derived from Dalbergia ecastaphyllum plant resin, has 
high relative percentages of the isoflavonoids 3-hydroxy-8,9-dimethoxypterocarpan 
and medicarpin95. Other flavonoids commonly present include galangin and 
pinocembrin96. Caffeic acid phenethyl ester (CAPE) is also a component of some 
varieties of propolis from New Zealand97. 
Medical uses 
Propolis has been used in traditional medicines for thousands of years98,99. The 
National Institutes of Health rates propolis as "possibly effective" for treating cold 
sores, genital herpes, and post-surgery mouth pain. Propolis is also used to make 
cough drops for cough and throat irritation100. Currently, there is "insufficient 
evidence" to rate the effectiveness of propolis in treating other conditions101. 
Biomedical research 
Propolis is being researched for the potential development of new drugs 
focusing on a variety of its properties, including those for possible 
immunomodulatory, anti-diabetic and anti-ulcer applications102. 
Beneficial effects of propolis on human health and neurological diseases 
Propolis is a natural product, collected by honeybees Apis mellifera, from 
various plant sources. Propolis is extensively used in foods and beverages because it 
improves human health. It contains more than 300 natural compounds such as 
polyphenols, phenolic aldehydes, sequiterpene-quinones, coumarins, amino acids, 
steroids and inorganic compounds. Propolis exhibits a broad spectrum of biological 
and pharmacological properties such as antimicrobial, antioxidant, anti-inflammatory, 
immunomodulatory, antitumor, anticancer, antiulcer, hepatoprotective, cardio-
protective, and neuroprotective actions. The chemical composition and beneficial 
properties of propolis vary greatly depending on the phytogeographical areas, 
seasonal collection time, and botanical source. Polyphenols found in fruits and 
vegetables are beginning to receive increased attention due to their vital role in 
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protecting neural cells from oxidative stress and neuroinflammation associated with 
normal aging and chronic age-related diseases. Propolis is one of the most abundant 
sources of polyphenols (mainly flavonoids and phenolic acids). This overview is an 
attempt to discuss the molecular mechanism underlying the potential beneficial effects 
of propolis on human health and neurological diseases. 
Propolis is used for canker sores and infections caused by bacteria (including 
tuberculosis), by viruses (including flu, H1N1 "swine" flu, and the common cold), by 
fungus, and by single-celled organisms called protozoans. Propolis is also used for 
cancer of the nose and throat; for boosting the immune system; and for treating 
gastrointestinal (GI) problems including Helicobacter pylori infection in peptic ulcer 
disease. Propolis is also used as an antioxidant and anti-inflammatory agent. 
People sometimes apply propolis directly to the skin for wound cleansing, 
genital herpes and cold sores; as a mouth rinse for speeding healing following oral 
surgery; and for the treatment of minor burns.Propolis seems to have activity against 
bacteria, viruses, and fungi. It might also have anti-inflammatory effects and help skin 
heal. 
Propolis is possibly safe when taken by mouth or applied to the skin 
appropriately. It can cause allergic reactions, particularly in people who are allergic to 
bees or bee products. Lozenges containing propolis can cause irritation and mouth 
ulcers. 
Pregnancy and breast-feeding:  
There is not enough reliable information about the safety of taking propolis if 
you are pregnant or breast-feeding. Stay on the safe side and avoid use. 
Asthma:  
Some experts believe certain chemicals in propolis may make asthma worse. 
Avoid using propolis if you have asthma. 
Bleeding conditions:  
A certain chemical in propolis might slow blood clotting. Taking propolis 
might increase the risk of bleeding in people with bleeding disorders. 
Allergies:  
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Do not use propolis if you are allergic to bee by-products including honey, 
conifers, poplars, Peru balsam, and salicylates. 
Surgery:  
A certain chemical in propolis might slow blood clotting. Taking propolis 
might increase the risk of bleeding during and after surgery. Stop taking propolis 2 
weeks before surgery. 
Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) 
Propolis might slow blood clotting and increase bleeding time. Taking 
propolis along with medications that also slow clotting might increase the chances of 
bruising and bleeding. Some medications that slow blood clotting include aspirin, 
clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, ticlopidine 
(Ticlid), warfarin (Coumadin), and others. 
Propolis might increase the amount of time it takes for blood to clot. Taking it 
along with other herbs and supplements that slow blood clotting can slow blood 
clotting even more and could increase the risk of bleeding and bruising in some 
people. Some of these herbs include angelica, clove, danshen, garlic, ginger, ginkgo, 
Panax ginseng, and others. 
Applied to the skin: 
 For cold sores: A 3% propolis ointment (Herstat or ColdSore-FX) applied 5 
times daily. 
 For herpes outbreak: A 3% propolis ointment (Herstat or ColdSore-FX) 
applied to the blisters 4 times daily. 
 As a mouth rinse after mouth surgery: A solution containing propolis, water, 
and alcohol. 
Other names 
Acide de Cire d'Abeille, Baume de Propolis, Bee Glue, Bee Propolis, Beeswax 
Acid, Cire d'Abeille Synthétique, Cire de Propolis, Colle d'Abeille, Hive Dross, 
Pénicilline Russe, Propóleos, Propolis Balsam, Propolis Cera, Propolis d'Abeille, 
Propolis Resin, Propolis Wax, Résine de Propolis, Russian Penicillin, Synthetic 
Beeswax. 
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Methodology 
To learn more about how this article was written, please see the Natural 
Medicines Comprehensive Database methodology. 
 
 
Fig. 8 
As an Antioxidant, bee propolis neutralizes free radicals that would otherwise 
damage molecules and lead to cell damage known to cause degenerative conditions. 
As an Antimicrobial agent, bee propolis was shown in a test for anti-microbial 
action to diminish the growth of various bacteria, yeast, and fungus responsible for 
common ailments such as dental caries, vaginal yeast infections, salmonella, and 
stomach ulcers. 
In addition, scientific trials and studies also suggest bee propolis can 
accelerate wound healing in diabetes, promote healthy cells, reduce outbreaks from 
mouth ulcers (RAC), and reduce inflammation associated with various conditions. 
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REVIEW OF LITERATURE 
Propolis is the bee product with the highest antimicrobial activity. The 
antibacterial activity of propolis has been confirmed by numerous scientific studies. 
Antibacterial activity has been demonstrated against both gram positive and gram-
positive, both aerobic and anaerobic types. Although the composition of propolis 
differs considerably depending on its botanical origin, all examined types of propolis 
revealed a strong antibacterial activity103,104. 
The antibacterial activity of poplar propolis and other types of propolis of different 
geographical and botanical origin was similar105. 
Poplar propolis gathered by Apis mellifera caucasica had a higher antibacterial 
activity than the one gathered by Apis mellifera anatolica and Apis mellifera 
carnica106 
More recent research has revealed antibacterial activity against Micrococcus 
luteus, Salmonella typhimurium107Klesbsiella pneumonae108. In recent study, it has 
been shown that propolis has a stong antibacterial activity against109 different plant 
pathogens110 propolis is also based on quorum sensing inhibitory (QSI) action, the 
flavonoid pinocembrin being an important QSI agent111. 
Generally, biologically activity decreases with increasing storage. However it 
was found that propolis solution in ethanol stored for 10-15 years results not in result 
in a decrease, but in an increase of antibacterial activity112. 
Antifungal activity 
Poplar propolis is the bee product with the highest antifungal activity as tested 
with 40 yeast strains of Candida albicans, Candida glabrata, Candida krusei, and 
Trichosporon spp113. 
Antivirus activity 
Propolis kills the fungi and also the viruses, while the growth of the latter is 
also inhibited114. Propolis acts against many different viruses. Most notable is its 
activity against the influenza virus, found in propolis of different origin115 and in 
Brazilian green propolis296 CAPE, a poplar propolis constituent is a prominent 
antiviral substance116. 
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Antioxidant activity 
An antioxidant is a molecule capable of slowing or preventing the oxidation of 
other molecules and so to prevent such changes. The antioxidant effect correlates 
roughly with the anti-inflammatory and hepatoprotective activity. 
Although the phenolic content seems to vary according to the botanical origin, 
antioxidant effects for most propolis types have been reported. 
Compared to pollen and royal jelly, propolis extracts exhibited the highest antioxidant 
activity117. 
Hepatoprotective activity and anti-radiation activity 
The liver is perhaps the hardest working organ of the body. It has hundreds of 
tasks to perform, including detoxification of the blood. A sluggish liver means fatigue 
and toxemia and a high risk of various chronic diseases. Phenolics are known to have 
a hepatoprotective function. Hepatoproctive activity for different types ofpropolis has 
been reported, which correlated to the antioxidant activity118-120. Propolis counteracts 
hepatoxic effects of alcohol liver injury in mice and also of paracetamol induced liver 
damage of mice111 and carbon tetrachloride induced liver damages in rats121. 
The anti-radiation effect of propolis have been reviewed by Orsolic in 2010. 
As an antioxidant propolis has a powerful effect to counteract radiation as tested in 
tumor cells or animals. Propolis act also in apoptosis (cell death) of cancer cells thus 
improving the anti-cancer effect of radiation122. 
Propolis supplementation is prophylactic for liver health and for counteracting the 
damaging effect of tumor irradiation. 
Immunomodulating effects 
The immunomodulating effect has been reviewed in 2007 by Sforcin123. All 
propolis types have immune stimulating activity. However, the active substances of 
the various types of propolis are different. 
Action on microphages 
In vitro and in vivo assays demonstrated the modulatory action of propolis on 
murine peritoneal macrophages,increasing their microbicidal activity and stimulating 
the lytic activity of natural killer cells against tumor cellsby enhancing antibody 
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production. The best immunostimulating results were observed when propolis was 
administered over a short-term to animals. Both poplar and baccharis propolis 
increase the microphage activity123. 
Action on lymphocytes and antibody production 
Both poplar and baccharis propolis can have an immunostimulalting effect by 
increasing antibody production and by activating B and T lymphocytes, an adjuvant 
like activity of propolis. The propolis compoundschrysine, quercetin, and galangin 
have a antiparasitic activity124. 
Propolis can be regarded as a supplement for the stimulation of the immune system. 
Antitumor effects 
The antitumor activity of propolis has been reviewed Orsolic, 2010, shows 
that the chemopreventive activity of propolis in animal models and cell cultures are 
likelyto be the result of their ability to inhibit DNA synthesis in tumour cells, their 
capability to induce apoptosis (cell death) of tumour cells, and their property to 
activate macrophages to produce factors capable of regulating thefunction of B-, T- 
and NK-cells, respectively. Especially interesting is the synergy between propolis and 
anticancer agents. Moreover, flavonoids from propolis play a protective role against 
the toxicity of the chemotherapeutic agents or radiation in mice, giving hope that they 
may have similar protective action in humans. The combination with an adjuvant 
antioxidant therapy may enhance the effectiveness of chemotherapy by ameliorating 
the side effect on leukocytes, liver and kidneys and consequently enabling dose 
escalation. 
Many polyphenols have an anti-metastatic activity, caffeic acid phenethyl 
ester (CAPE) from poplar propolis and Artepillin C from baccharis propolis has been 
identified as the most potent antitumor agents125. But antitumor effects of chrysin 
(poplar propolis) and both nemorosone and plukenetione A (inCuban propolis) have 
been reported. Regular consumption of propolis food supplements can have a 
preventive effect against mutation linked cancers in humans126. 
Propolis can be regarded as a supplement for cancer prevention. 
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PLAN OF WORK 
Propolis, sometimes also called “bee glue”, is a strongly adhesive, resinous 
substance that honeybees collect from various plants, transformed and used by bees to 
seal holes in their honeycombs, to smooth out the beehive’s internal walls and to 
protect the entrance against intruders. Honeybees (Apismellifera L.) collect the resin 
from cracks in plant barks and leaf buds. They masticate the resin and by doing so 
they add salivary enzymes to it. After this, they mix the partially digested material 
with beeswax and use it in their hive.  
Propolis is a mixture of various amounts of beeswax and resins collected by 
the honeybee from plants, particularly from flowers and leaf buds. Since it is difficult 
to observe bees on their foraging trips the exact sources of the resins are usually not 
known. Bees have been observed scraping the protective resins of flower and leaf 
buds with their mandibles and then carrying them to the hive like pollen pellets on 
their hind legs. It can be assumed that in the process of collecting and modeling the 
resins, they are mixed with some saliva and other secretions of the bees as well as 
with wax.  
 Propolis is widely used in Indian folk medicine for the treatment of various 
illness. The preventive and curative effects of Indian propolis (Propolis samples from 
Mudivaithanendal, Tamil Nadu) for immunomodulatory activity were evaluated using 
models of cyclophosphamide treated immunosuppressed rats.  
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PREPARATION OF EXTRACT 
Ethanolic extracts of Propolis (yield = 7.5%) wereprepared by routine methods 
using rotary vacuum evaporator (Roteva, Equitron, Medica Instruments Mfg. Co, 
Mumbai) and programmable freeze dryer (Allied Frost, Mumbai) from dried Propolis. 
Powders of Propolis extracts are light brown color. 
Propolis extracts were stored in a refrigerator at 4°C to protect from light 
anddegeneration, and they are well soluble upto 60mg/mL concentration levels 
indistilled water used as vehicle as clear light brown solution. 
Extraction Procedure 
The fresh Propolis were collected and authenticated. ThePropolis was dried in 
the shade. 
Materials 
 Rotary Evaporator 
 70% ethanol 
 Shade Propolis 
Methods 
500gm of Propolis extracted with 2liters of 70% Ethanol at 70°C temperature, 
for 1 hour in a 2 liter round bottom flaskwith condenser attached. Filter and collect the 
extract. Filter and collect the extract. Theextract was evaporated to drynessunder 
reduced pressure in a Buchi Rotary Evaporator (Switzerland) at 65°C, to obtain 
brownish colour residue. This extract was used for the experimentation. 
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PHARMACOLOGICAL EVALUATION 
Experimental animals 
The immunomodulatory study was conducted in Swiss albino rats (180-220 g) 
of either sex. The experimental protocol was approved by the Institutional ethical 
committee. All animals were housed at 25 ± 5°C in a well-ventilated animal house 
under 12/12 h light/dark cycle with standard commercial diet as per the ethical 
guidelines. Animals were acclimatized to the experimental conditions for one week 
before starting the study to reduce animal stress.  
Experimental design 
The immunomodulatory activity of Propolis was tested on Cyclophosphamide-
treated immune suppressed rat model. The Swiss albino rats were divided into six 
groups and each group contained 6 animals.  
The groups are as follows:  
• Group I served as a control received saline solution.  
• Group II served as an immuno- suppressant group, received 
cyclophosphamide at the dosage of (30 mg/kg, i.p.)  
• Group III served as a parse control which received Propolis (50mg/kg, i.p).  
• Groups IV and V served as the test groups which were immune-suppressed 
with cyclophosphamide (30 mg/kg, i.p) and treated with Propolis (50 and 100 
mg/kg, i.p), respectively.  
• Group VI served as the positive control which received cyclophosphamide (30 
mg/kg, i.p) along with Standard drug-levamisole hydrochloride (LH) (10 
mg/kg bw, i.p).  
All the groups treated with Propolis and levamisole hydrochloride were 
injected on daily basis for 11 days, while cyclophosphamide was given on4,5 and 6th 
days of the experiment.  
At the end of the experiment, the animals were sacrificed by cervical 
dislocation and the blood was collected using heart puncher in 3% citrate containing 
tubes. The organs namely liver, spleen, heart and kidney were immediately collected, 
weighed and stored at 8°C.  
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Body weight and relative organ weight determination 
Body weight and relative organs (Spleen, liver, Heart, Kidney) weight were 
measured for all animals and the results were expressed as mg of organ weight/g body 
weight of animal,  
Organ weight index= W1/W0 × 100,  
where W1 is the weight of Organ and W0 is the weight of body  
Histopathological examinations  
The liver and spleen tissue slices was dissected and fixed in 10% formalin, 
embedded in paraffin, sectioned to 4 mm thickness, deparaffinized, rehydrated using 
standard techniques and finally stained with hematoxylin and eosin. The histological 
changes in the liver and spleen were examined using light microscopy.  
Hematological analysis 
The level of WBC, RBC, platelet and heamoglobin level were determined 
using an automatic cell counter. 
Effect of Propolis on cell mediated immune response 
Immunization 
About 5µg of hepatitis B vaccine (Revac-B, from Bharat Biotech, India) was 
given as antigen on the 4th day (IM) of the experiment. The vaccine contained 
aluminum hydroxide as an adjuvant and were preserved with thiomersal.  
Cellular immune response  
Delayed type Hypersensitivity reaction 
The cell mediated immune response was assessed by footpad reaction test. On 
the 10th day, 5µg of hepatitis B vaccine was injected in the right paw and saline was 
injected in the left paw. On the 11th day after 24 h, the paw volume was measured 
using plethysmometer and the results were expressed as % of increase in the paw 
volume.  
Phagocytic response  
The phagocytic response was determined according to the method of Wang et 
al (2012)127. On the 7th day of the experiment, the animals were injected with 100 
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µlof Indian ink via intravenous injection. 50µl of blood was collected with 5µl of 3% 
citrate by retro-orbital puncher at an interval of 2 and 30 minutes after the injection of 
ink. Then 25 µl of citrated blood was added to 3 ml of 0.1% sodium carbonate 
solution to lyse the RBC. The concentration of ink in the blood was read at A675nm 
using spectrophotometer.  
The carbon clearance rate (κ) and phagocytic index (α) were calculated by 
using the following formula:  
Rate of carbon clearance (κ) = (1−log2)/(1−2)  
where OD1 is the absorbance at 2 minutes; OD2 is the absorbance at 30 
minutes; T1 is the time of blood collection at 2 minutes; T2 is the time of blood 
collection at 30 minutes  
Phagocytic index α =( ∛×	)/(
+)  
where A is the body weight, B is the liver weight, and C is the spleen weight.  
Total antioxidant status of organs 
Tissue Homogenate preparation 
The liver was homogenized in 50 mM phosphate buffered saline (pH 7.4) by 
using chilled mortar and pestle at 4°C. The homogenate was centrifuged at 2000 x g 
for 10 minutes at 4°C. The supernatant was used for the determination of antioxidant 
status of the organs.  
Total glutathione level  
Estimation of the reduced glutathione (GSH) level was done according to the 
method of Ellman (1959)128. Briefly, 400µl of the tissue homogenate was treated with 
400µl of 5% sulphosalicylic acid and mixed well with vortex. Then the mixture was 
centrifuged at 1000 x g for 10 minutes at 4°C. 100 µl of the supernatant was mixed 
with 400 µl of 0.3 M phosphate buffer (pH 8.4) and 400 µl of distilled water. Then 
100 µl of 0.001 M freshly prepared DTNB (5,5-dithiobis (2-nitrobenzoic acid)) was 
added and kept in room temperature for 10 minutes. The formation of yellow coloured 
product was measured at 412nm. The amount of glutathione present in the tissue 
homogenate was calculated by constructing standard graph with glutathione and the 
results were expressed as µM/mg of protein.  
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Lipid peroxidation  
The amount of lipid peroxide present in the tissue was estimated according to 
the method of Stocks and Dormandy (1971)129. Briefly, 400 µl of the tissue 
homogenate was mixed with an equal volume of 10 % Trichloro acetic acid and kept 
in 4°C for 30 minutes. The proteins were removed by centrifugation at 2000 × g for 
10 minutes at 4°C. 500 µl of 1% thiobarbituric acid was added to 500 µl of the 
supernatent and the mixture was kept in boiling water bath for 30 minutes. The 
reaction mixture was cooled and centrifuged at 2000 × g for 10 minutes at 4°C. The 
absorbance of the supernatant was measured at 532 nm using a spectrophotometer. 
The concentration of lipid peroxide was calculated using molar extinction coefficient 
of MDA-thiobarbituric chromophore (1.56 x 10-5/M/cm) and the results were 
expressed in terms of nmoles MDA/mg of protein.  
Carbonyl protein  
The level of protein damage was determined by carbonyl protein estimation 
according to the method of Reznick and Packer (1994)130. Briefly 200µl of the tissue 
homogenate was treated with 200µl of 1% trichloro acetic acid and was kept at 4°C 
for 30 minutes. The mixture was centrifuged at 2000 x g for 15 minutes and the pellet 
was re-suspended in 10 mM 2,4-dinitrophenylhydrazine in 2N HCl or with 2N HCl as 
a control blank. This mixture was kept in room temperature for 1 hour and then 
centrifuged at 2000 x g for 10 minutes. The pellet was washed three times with 1:1 
ethanol/ethylacetate solution. Finally, the carbonyl protein containing the pellet was 
dissolved in 6 M Guanidine. The protein hydrazones were measured at A370 nm 
using spectrophotometer. The amount of carbonyl protein was calculated from molar 
extinction coefficient of 22,000 M−1 cm−1 and the results were expressed as µg/mg 
of protein.  
Superoxide Dismutase activity  
The level of superoxide dismutase in the tissue was estimated according to the 
method of McCord and Fridovich (1969)131. This method is based on the ability of the 
enzyme to inhibit the auto-oxidation of pyrogallol. Briefly, 100µl of the tissue 
homogenate was added to 700 µl of 100 mM of Tris-HCl buffer (pH 8.2) containing 
30 mM EDTA. Then, 200µl of 2 mM of pyrogallol was added to the solution and 
measured at 420nm for 60 sec using spectrophotometer. A blank was run without the 
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addition of homogenate. One unit of SOD activity is the amount of enzyme capable of 
inhibiting 50% of the rate of autoxidation of pyrogallol compared with the blank and 
are expressed as units’/mg protein/min. 
Catalase activity  
The catalase level in the tissue homogenate was estimated according to the 
method of Sinha (1972)132 with minor modification. Briefly, add 100 µl of tissue 
homogenate to 300 µl of 50 mM phosphate buffer pH-7. Then, 100 µl of 200mM 
H2O2 was added to the mixture, mix well and placed it in room temperature for 30 
sec. Immediately, after 30 secs, add 500 µl of 1.5% potassium dichromate / acetic acid 
(weight/volume). The mixture was kept in boiling water bath for 10 minutes and 
cooled. The absorbance was read at 590 nm against blank using spectrophotometer. 
The different concentration of H2O2 (1-50 µM) was used for construct the standard 
graph and the catalase activity was calculated from the standard graph of H2O2 (1-50 
µM) and results were expressed as µmole of H2O2 consumed/ mg of protein/ minute.  
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RESULTS AND DISCUSSION 
The immune system plays an important role in defense mechanism and 
protects the body against various antigens and infectious diseases. The homeostatic 
balance is maintained by the stimulation or suppression of immune cells and it keeps 
the body in normal healthy condition. Thus, the immune modulator plays a vital role 
in maintaining the immune system.  
In this study, the immunomodulatory activity of purified Propolis was studied 
on cyclophosphamide (CYP) treated immuno-suppressed Swiss albino rats. The 
immunomodulatory activity of Propolis was compared with standard immune 
activating drug levamisole.  
The CYP is an alkylating drug that belongs to the subclass of nitrogen 
mustard. It is commonly given as a chemotherapeutic drug for cancer treatment and as 
an immunosuppressant for organ transplantation and autoimmune disorder (Moore 
1991)133. CYP also causes some side effects such as myelosuppression, immune 
suppression and oxidative stress which may be life threatening (Wang et al 2011)134. 
The inactive form of CYP is activated by the liver enzyme cytochrome P450 to 4-
hydroxycyclophosphamide which transferred to other organs as well. Then, 4-
hydroxycyclophosphamide is further converted to phosphoramide mustard and 
acrolein. The phosphoramide mustard causes cytotoxic damage to cells and acrolein 
causes some side effects (Sun & Peng 2008)135.  
In this study, CYP is given to the Swiss albino rats to suppress the immune 
system and induce oxidative stress. The cyclophosphamide effect is expected to 
reduce the activity of hematological parameters, cell mediated immune responses and 
macrophage production. Moreover, CYP impaired the organs through its toxic 
metabolites and caused oxidative stress. The effect of Propolison CYP induced 
immune-toxicity was examined through myelosuppression, immune suppression and 
oxidative damage.  
  
Results & Discussion 
 
35 
 
Table No. 2 Effect on Propolis on Haemoglobin level 
Groups Haemoglobin (g/dl) 
G1 13.40 ± 0.30 
G2 10.90 ± 0.22*a 
G3 12.85 ± 0.28*b 
G4 12.90 ± 0.26*b 
G5 13.05 ± 0.29*b 
G6 13.20 ± 0.28*b 
*a = P < 0.05 compared with normal control 
*b = P < 0.05 compared with negative control 
 
 
Fig. 9 Effect of Propolis on hematopoietic function against cyclophosphamide -treated 
rats. G1-normal control; G2-Negative control (30mg/kg.b.w. CYP alone treated); G3- 
Perse control (50 mg/kg b.w. Propolis alone); G4- 50 mg/kg b.w. Propolis + 30mg/kg 
b.w. CYP; G5- 100 mg/kg b.w. Propolis + 30mg/kg b.w. CYP; G6-10 mg/kg b.w. 
Levamisole+ 30mg/kg b.w. CYP. Values are expressed as the mean ± S.D. for n = 6 
Significance was determined by one-way analysis of ANOVA followed by post-hoc 
analysis using Newmann Keul’s multiple range tests  
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Table No. 3 Effect on Propolis on RBC level 
Groups RBC (106/µL) 
G1 7.85 ± 0.16 
G2 6.72 ± 0.08*a 
G3 8.10 ± 0.12*b 
G4 7.60 ± 0.10*b 
G5 7.55 ± 0.14*b 
G6 7.75 ± 0.10*b 
*a = P < 0.05 compared with normal control 
*b = P < 0.05 compared with negative control 
 
 
Fig. 10 Effect of Propolis on hematopoietic function against cyclophosphamide -
treated rats.G1-normal control; G2-Negative control (30mg/kg.b.w. CYP alone 
treated); G3- Perse control (50 mg/kg b.w. Propolis alone); G4- 50 mg/kg b.w. 
Propolis + 30mg/kg b.w. CYP; G5- 100 mg/kg b.w. Propolis + 30mg/kg b.w. CYP; 
G6-10 mg/kg b.w. Levamisole+ 30mg/kg b.w. CYP. Values are expressed as the 
mean ± S.D. for n = 6 Significance was determined by one-way analysis of ANOVA 
followed by post-hoc analysis using Newmann Keul’s multiple range tests  
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Table No. 4 Effect on Propolis on WBC level 
Groups WBC (106/mL) 
G1 7.30 ± 0.22 
G2 3.45 ± 0.15*a 
G3 6.55 ± 0.18*b 
G4 6.90 ± 0.20*b 
G5 7.05 ± 0.21*b 
G6 6.80 ± 0.19*b 
*a = P < 0.05 compared with normal control 
*b = P < 0.05 compared with negative control 
 
 
Fig. 11 Effect of Propolis on hematopoietic function against cyclophosphamide -
treated rats.G1-normal control; G2-Negative control (30mg/kg.b.w. CYP alone 
treated); G3- Perse control (50 mg/kg b.w. Propolis alone); G4- 50 mg/kg b.w. 
Propolis + 30mg/kg b.w. CYP; G5- 100 mg/kg b.w. Propolis + 30mg/kg b.w. CYP; 
G6-10 mg/kg b.w. Levamisole+ 30mg/kg b.w. CYP. Values are expressed as the 
mean ± S.D. for n = 6 Significance was determined by one-way analysis of ANOVA 
followed by post-hoc analysis using Newmann Keul’s multiple range tests  
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Table No. 5 Effect on Propolis on Platelets level 
Groups Platelets count (103/µL) 
G1 840.40 ± 10.50 
G2 560.90 ± 6.30*a 
G3 830.10 ± 9.60*b 
G4 790.20 ± 8.30*b 
G5 805.30 ± 8.50*b 
G6 802.60 ± 7.90*b 
*a = P < 0.05 compared with normal control 
*b = P < 0.05 compared with negative control 
 
 
Fig. 12 Effect of Propolis on hematopoietic function against cyclophosphamide -
treated rats G1-normal control; G2-Negative control (30mg/kg.b.w. CYP alone 
treated); G3- Perse control (50 mg/kg b.w. Propolis alone); G4- 50 mg/kg b.w. 
Propolis + 30mg/kg b.w. CYP; G5- 100 mg/kg b.w. Propolis + 30mg/kg b.w. CYP; 
G6-10 mg/kg b.w. Levamisole+ 30mg/kg b.w. CYP. Values are expressed as the 
mean ± S.D. for n = 6 Significance was determined by one-way analysis of ANOVA 
followed by post-hoc analysis using Newmann Keul’s multiple range tests  
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Effect of Propolis on hematopoietic function against cyclophosphamide induced 
immune-toxicity 
The protective effect of Propolis on hematopoietic function against CYP 
induced immune-toxicity was evaluated by counting the level of hematological 
parameters like (Haemoglobin) Hb, RBC, WBC and platelet cells. The results of 
hematological analysis showed that the level of Hb, RBC, WBC and platelet cells 
were significantly reduced in negative control group of animals (G2- CYP alone 
treated) when compared to normal control group of animals (G1-Saline alone) 
(P<0.01) (Fig. 9,10,11,12). However, these levels were raised significantly in Propolis 
treated group of animals (G4 =50 (mg/kg b.w.), and G5 = 100 (mg/kg b.w.) in a dose 
dependent manner. The increase in the levels of hematological parameters in group of 
animals of G4 and G5were significant with the negative control group of animals 
(G2) (P<0.01). The levels of hematological parameters in Propolis50 (mg/kg b.w.) 
alone treated group of animals (G3) was on par normal control group of animals (G1). 
The hematological parameters in positive control groups of animals (G6) which are 
treated with standard drug levamisole (10mg/kg) showed significant recovery when 
compared to negative control group of animals (G2) (P<0.05). 
The alkylating nature of the CYP, alkylates the DNA and interferes in the 
synthesis and proliferation of hematopoitic cells leading to myelosuppression. 
Myelosuppression is the process of decreasing the production of immune cells 
(leukocytes), oxygen carrying cells (erythrocytes) and the cells responsible for blood 
clot (thrombocytes) (Urabe 2003)136. The results of this study showed that the groups 
treated with Propolis have improved the production of hematopoietic cells like RBC, 
WBC, platelets and hemoglobin. The hematopoietic stem cells possess 
multipotentiality and have the capacity to renew the hematological parameters such as 
RBC, WBC and platelets. The increase in levels of Hb, RBC, WBC and platelets 
might have taken place due to induction of hematopoietic stem cells by Propolis. 
Byon et al (2008)137 and Frenette and Weiss (2000)138 have reported induction of 
mobilization of hematopoietic progenitor cells and boost the immunity by fucoidan 
from brown algae. The hematological results reveal that the Propolis has protective 
effect against CYP induced myelosuppression.  
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Effect of Propolis on cell mediated immunity against cyclophosphamide -treated 
immunosuppressed rats 
The cell mediated immune response is induced by T lymphocytes and their 
products (lymphokines). These cells are involved in the effector mechanism which 
provides defense against the infectious organisms, foreign grafts, cancer cells and are 
also involved in delayed type hypersensitivity reaction (Miller & Peacock 1991)139. 
The cell mediated immune response was determined by delayed type hypersensitivity 
reaction (DTH) by measuring their footpad thickness. 36% decrease in the paw 
volume of negative control group of animals (G2) was observed when compared to 
the normal control group of animals (G1) (P< 0.05). The thickness of footpad 
increased significantly in the groups (G4 and G5) treated with Propolis in a dose 
dependent manner in comparison with negative group of animals (G2). The footpad 
volume of 50 (mg/kg b.w.) (G4) and 100 (mg/kg b.w.) (G5) treated group of animals 
were 30% and 43% higher, respectively (P < 0.01 in every group), when compared to 
negative control group of animals (G2). The footpad volume of 100 (mg/kg b.w) (G5) 
treated group of animals showed 11% higher than that of normal control group of 
animals (G1) (P< 0.01). The levamisole treated group also showed similar results (i.e) 
36% higher footpad volume than control group (P<0.01). The group of animals 
treated with Propolis alone (G3) showed 33% higher footpad volume than the normal 
control group of animals. The above results also supported by Kim and Joo (2008)140 
who demonstrated cytotoxic T cells enhancing property of fucoidan from C. 
okamuranus. Wang et al (1994)141 also reported immune boosting property of 
fucoidan from L. japonica on immune suppressed mice by activating the macrophage 
and T- lymphocyte. In this study, the Propolis has enhance the cell mediated immune 
response through the activation of T-cell.  
Effect of Propolis on phagocytic response against cyclophosphamide -treated 
immunosuppressed rats 
Phagocytosis is a process by which immune system effectively remove or 
engulf microorganisms, cancer cells, inorganic particles and tissue debris. The 
phagocytic test is used to evaluate the non- specific immunity of the system. The 
immune cells involved in phagocytosis are called phagocytes (Miller & Peacock 
1991)139. The macrophages are the major phagocytic cells (neutrophils, monocytes 
and macrophages). The phagocytic index is calculated from the rate of clearance of 
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colloidal carbon particles from the circulatory system. The phagocytic index (α) of 
CYP treated group of animals showed significant decrease (39%) when compared to 
normal control group of animals (P< 0.05). It indicates that the effect of CYP 
impaired the immune system and suppressed the levels of phagocytes. The Propolis 
significantly restored the level of phagocytic index when compared with negative 
control group of animals (G2) (P< 0.05 with each group). The Propolis at the 
concentration of 50 (mg/kg b.w), 100 (mg/kg b.w) increased the phagocytic index up 
to 11% and 29% when compared to negative control group of animals (G2). 
Moreover, the 50mg/kg Propolis treated groups showed 8% elevated phagocytic 
activity (P<0.05) than the control group. The standard drug levamisole showed 11.5% 
increased phagocytic activity than the normal control group. Propolis 4 times higher 
than that of normal control group at a dose 50mg/kg (Chen et al 2012)142. Several 
authors reported that fucoidan from brown algae have the potency to activate and 
proliferate the phagocytic system (Song et al 2000; Teruya et al 2009; Wang et al 
1994; Yang et al 1995)143-146. The results carbon clearance test indicates that Propolis 
can enhance non-specific immune response against CYP induced 
immunosuppression.  
Effect of Propolis on organ weight index against cyclophosphamide -treated 
immunosuppressed rats:  
The weight index of organs like spleen, liver, kidney and heart reflects the 
health of the organism. The toxic metabolite produced from CYP is initially 
metabolized in liver and produces toxic metabolite which is further transferred to 
other organs. The toxic metabolites primarily impair the immune organs such as liver, 
spleen and merely affect kidney and heart (Sun & Peng 2008)135. In the present study, 
it was showed that the weight index of the organs like spleen and liver involved in the 
immune system was significantly reduced in CYP alone treated group of animals (G2) 
compared to the normal control group of animals (G1) (P<0.05). The weight index 
reduction of organs like kidney and heart is less when compared to the weight index 
reduction of liver and spleen. Kanno et al (2009)147 reported that CYP impose higher 
impact on the reduction of weight index of liver than on other organs like kidney, 
heart and lungs. These findings integrate with the results of the present study. The 
groups of animals given with Propolis alone (G3) did not make much difference on 
the organ weight. The treatment with Propolis (G4 and G5) improved the spleen and 
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liver weight significantly compared to negative control group of animals (G2) 
(P<0.05). The rate of index of organ weight recovery was based on their 
concentration. The results of organ weight index showed that the suppressed health 
due to CYP induced oxidative stress have recovered to normal after Propolis 
treatment.  
Effect of Propolis on antioxidant status of organs against cyclophosphamide 
induced oxidative stress 
The antioxidant status acts in connection with many diseases and cause 
immune dysfunction. The drugs like cisplatin, cyclophosphamide or corticosteroids 
used for immunosuppression generates free radicles (reactive oxygen species) and 
toxic metabolites (Gate et al 1999)148. The imbalance between the reactive oxygen 
species and antioxidant defense mechanism causes oxidative stress exhibiting 
inflammatory response and the resulting tissue and cell injury (Cotran et al 1999)149. 
The increased ROS generation will damage macromolecules like lipid, DNA and 
protein in the tissue. (Colvin 1999)150. The immunomodulator from plant origin have 
the capacity to reduce the oxidative stress through antioxidant mechanism 
(Joharapurkar et al 2004)151. Moreover, Propolis has shown comparably good 
superoxide radical scavenging capacity and other antioxidant activities. The effect of 
Propolis against oxidative stress caused by CYP treatment was assessed by the 
determination of enzymatic and non-enzymatic antioxidant status and levels of 
macromolecular damage. 
Effect of Propolis on non-enzymatic antioxidant status of liver organ  
The non-enzymatic antioxidant status plays a major role in maintaining the 
innate antioxidant status (Williams & Burk 1990)152. Glutathione belongs to non-
enzymatic antioxidant and also repairs the immunological and neurodegenerative 
disorders (Raghavendra & Kulkarni 2001)153. Reduced glutathione level is a suitable 
indicator for overall antioxidant defense which maintains alpha-tocopherol and 
ascorbic acid and is also a coenzyme for glutathione S-transferases and glutathione 
peroxidases(Jones 2002)154.  
The level of glutathione was significantly reduced in liver of negative control 
group of animals (G2) (liver= 20.50±1.05) compared to the normal control group of 
animals (P<0.05) (liver = 36.60±1.45). The Propolis treatment on CYP intoxicated 
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group of animals (G4 and G5) directly increased the glutathione levels significantly 
based on the dose concentration in liver organs. 
Effect of Propolis on enzymatic antioxidant status of organ  
The groups of enzymes which are involved in the conversion of active oxygen 
molecule into non-toxic molecules are superoxide dismutase (SOD) and catalase 
(CAT). These enzymes maintain the enzymatic antioxidant status of tissue. The 
antioxidant enzyme superoxide dismutase coverts the superoxide to water peroxide 
whereas catalase converts hydrogen peroxide to water and oxygen. They are mainly 
located in peroxisomes, cytoplasm and mitochondria (Halliwell et al 1999)155. In this 
study, the levels of CAT significantly reduced in liver of negative control group of 
animals (G2) (liver = 1.36±0.24 (U/mg/min) compared to the normal control group 
(G1) (liver = 4.95±0.35 (U/mg/min) (P< 0.05). The Propolis treatment to animal (G4 
and G5) significantly restored the decreased CAT level to an equal or above the CAT 
levels of normal control group of animals in a dose-dependent manner (P < 0.05). 
(G6) of levamisole treated group of animals which are intoxicated with CYP showed 
7.2% higher CAT levels than the normal control group of animals (G1). The CAT 
levels in liver of Propolis alone treated group of animals (G3) was found high by 12.8 
% than that normal control group of animals (G1).  
Similarly, SOD levels were significantly reduced in liver negative control 
group of animals (G2) (liver = 40.30±2.60 (U/mg/min) when compared to the normal 
control group of animal (G1) (liver = 64.30±3.85 (U/mg/min) (P<0.05). Like that of 
CAT, the level of SOD significantly increased upon the dose dependent manner 
treatment with Propolis and attained the level of normal control group of animals at 
the concentration of 100mg/kg (P< 0.05). Similar to CAT, the Propolis alone treated 
group of animals (G3) did not show prominent change in the levels of SOD in liver 
tissues showed 22% higher SOD level than the normal control group of animals (G1).  
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Table No. 6 Effect of Propolis on enzymatic and non-enzymatic antioxidant status of 
liver tissue 
GROUPS Catalase 
U/mg of 
protein 
SOD 
U/mg of 
protein 
Glutathione 
U/mg of 
protein 
MDA  
M/mg of 
protein 
PCO 
ηM/mg of 
protein 
G1 4.95±0.35 64.30±3.85 36.60±1.45 7.35±0.40 3.20±0.15 
G2 1.36±0.24*a 40.30±2.60*a 20.50±1.05*a 14.80±0.85*a 6.55±0.28*a 
G3 3.85±0.30*b 56.22±2.90*b 32.40±1.30*b 12.60±0.65*b 5.40±0.18*b 
G4 3.60±0.28*b 56.60±2.95*b 30.25±1.10*b 12.80±0.70*b 5.65±0.20*b 
G5 4.05±032*b 59.30±3.10*b 33.55±1.38*b 13.30±0.74*b 5.90±0.22*b 
G6 4.25±0.34*b 61.20±3.25*b 33.80±1.40*b 13.80±0.80*b 6.10±0.25*b 
*a = P < 0.05 compared with normal control 
*b = P < 0.05 compared with negative control 
G1-normal control; G2-Negative control (30mg/kg.b.w. CYP alone treated); G3- 
Perse control (50 mg/kg b.w. Propolis alone); G4- 50 mg/kg b.w. Propolis + 30mg/kg 
b.w. CYP; G5- 100 mg/kg b.w. Propolis + 30mg/kg b.w. CYP; G6-10 mg/kg b.w. 
Levamisole+ 30mg/kg b.w. CYP. Values are expressed as the mean ± S.D. for n = 6 
Significance was determined by one-way analysis of ANOVA followed by post-hoc 
analysis using Newmann Keul’s multiple range tests  
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Fig. 13 Effect of Propolis on the level of GSH in organs against cyclophosphamide 
induced oxidative stress on immunosuppressed rats 
 
 
 
Fig. 14 Effect of Propolis on the level of catalase in organs against cyclophosphamide 
induced oxidative stress on immunosuppressed rats. 
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Fig. 15 Effect of Propolis on the level of superoxide dismutase in organs against 
cyclophosphamide induced oxidative stress on immunosuppressed rats. 
Effect of Propolis on macromolecular damage of organ  
The important markers of oxidative stress are macromolecular like lipid and 
protein damage which produce lipid peroxide (MDA) and carbonyl protein (PCO) 
(Levine et al 1990; Reddy & Lokesh 1992)157,158. The MDA and PCO levels were 
found to be significantly increased in all the organs of the negative control group of 
animals (G2) compared to normal control group of animals (G1). The increase levels 
of MDA and PCO indicate that toxic metabolite produced from CYP induced 
oxidative stress damage the lipids and proteins present in the organ tissue. liver of 
negative control group of animals (G2) (liver= 14.80±0.85 (ηM/mg of protein)) 
showed almost 1.5- 2.2 times higher MDA level than that of the normal control group 
(G1) (P <0.05) (liver = 6.55±0.28 (ηM/mg of protein)). The levels of MDA were 
found decreased significantly in Propolis treated group of animals (G4 and G5) in 
dose dependent manner compared to negative control group, G2(P <0.05).  
Similarly, PCO levels significantly increased 1.5-2 times higher in liver of 
negative control group of animals (G2) (11.27±0.64 (µg/mg of protein), 10.49±0.52 
(µg/mg of protein), 7.79±0.31(µg/mg of protein)) compared to the normal control 
group of animals (G1) (6.87±0.43 (µg/mg of protein), 5.25±0.37 (µg/mg of protein), 
5.00±0.17 (µg/mg of protein). The increased levels of PCO on CYP toxicity decreased 
significantly on Propolis treatment in a dose dependent fashion (G4 and G5) (P<0.05).  
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The CYP toxicity induced high MDA and PCO levels were found normal at 
concentration of 100 (mg/kg b.w.) and 10 (mg/kg b.w) of Propolis and levamisole, 
respectively. Kim et al (2014)159 also reported that fucoidan significantly reduced 
MDA levels against 2,2-azobis dihydrochloride induced oxidative stress in zebrafish 
model. The fucoidan from C. okamuranus also reduce the MDA levels in Sparague-
Dowley (SD) rats (Thomes et al 2010)160.  
 
Fig. 16 Effect of Propolis on the level of MDA in organs against cyclophosphamide 
induced oxidative stress on immunosuppressed rats: 
 
 
Fig. 17 Effect of Propolis on the level of carbonyl protein of organs against 
cyclophosphamide induced oxidative stress on immunosuppressed rats: 
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HISTOPATHOLOGICAL ANALYSIS  
The morphological analysis of organs is studied further to investigate the 
effect of Propolis on the structural damage of organ due to CYP induced toxicity. The 
toxic metabolite produced by CYP is metabolized in liver and it transfers the reactive 
metabolites to the spleen.  
The Histopathological analysis of liver section of CYP treated animal showed 
white pulp and congested sinusoids and also showed toxic change like inflammation. 
The toxic change effected by CYP induced toxicity was gradually decreased upon 
treatment of Propolis (G4- 50 (mg/kg b.w.) and G5-100 (mg/kg b.w.). The Propolis 
alone treated group of animals (G3) did not show any characteristic change in the 
liver section compared to normal control group of animals (G1) (Fig. 18).  
The present study showed that the purified Propolis provide protection from 
oxidative stress triggered by CYP and recover the damage. CYP treatment 
significantly elevated the levels of macromolecule damage (MDA and PCO) and 
decrease the levels of enzymatic (SOD and CAT), non-enzymatic (GSH) antioxidant 
status in Liver. At the same time, Propolis treatment at the concentration of 100mg/kg 
b.w. reverse the effect of CYP induced damage via increasing CAT, SOD and GSH 
levels and thus protecting macromolecular damage and decrease MDA and PCO 
level. The morphological analysis also supports above study and shows the ability of 
Propolis to repair the damage caused by CYP induced oxidative stress.  
G1 section showed normal liver parenchyma with central vein and hepatocytes 
radiating from it; G2 section showed toxic change in liver due to CYP toxicity with 
portal triad showing mild inflammation; G3 section showed normal liver parenchyma 
with central vein and hepatocytes radiating from it; G4 and G5sections showed liver 
parenchyma with hepatocytes with slight, moderate and marked recovery respectively 
from CYP induced damage; G6 section showed liver parenchyma with central vein 
and hepatocytes exhibiting significant recovery from toxic change of CYP. 
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Fig. 18 Effect of Propolis on histopathological changes in the liver tissues against 
cyclophosphamide induced damage 
G1-normal control; G2-Negative control (30mg/kg.b.w. CYP alone treated); G3- 
Perse control (50 mg/kg b.w. Propolis alone); G4- 50 mg/kg b.w. Propolis + 30mg/kg 
b.w. CYP; G5 - 100 mg/kg b.w. Propolis + 30mg/kg b.w. CYP; G6-10 mg/kg b.w. 
Levamisole+ 30mg/kg b.w. CYP.  
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CONCLUSION 
In conclusion, the present study has proved that Propolis not only enhance the 
immune system but also protect the organs against oxidative stress. The results of the 
present study recommend that Propolis could be a prominent natural 
immunomodulating molecule with therapeutic value.  
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